Cargando…
Imaging, biomarker and invasive assessment of diffuse left ventricular myocardial fibrosis in atrial fibrillation
BACKGROUND: Using cardiovascular magnetic resonance imaging (CMR), it is possible to detect diffuse fibrosis of the left ventricle (LV) in patients with atrial fibrillation (AF), which may be independently associated with recurrence of AF after ablation. By conducting CMR, clinical, electrophysiolog...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008543/ https://www.ncbi.nlm.nih.gov/pubmed/32036784 http://dx.doi.org/10.1186/s12968-020-0603-y |
_version_ | 1783495488188710912 |
---|---|
author | Begg, Gordon A. Swoboda, Peter P. Karim, Rashed Oesterlein, Tobias Rhode, Kawal Holden, Arun V. Greenwood, John P. Shantsila, Eduard Lip, Gregory Y. H. Plein, Sven Tayebjee, Muzahir H. |
author_facet | Begg, Gordon A. Swoboda, Peter P. Karim, Rashed Oesterlein, Tobias Rhode, Kawal Holden, Arun V. Greenwood, John P. Shantsila, Eduard Lip, Gregory Y. H. Plein, Sven Tayebjee, Muzahir H. |
author_sort | Begg, Gordon A. |
collection | PubMed |
description | BACKGROUND: Using cardiovascular magnetic resonance imaging (CMR), it is possible to detect diffuse fibrosis of the left ventricle (LV) in patients with atrial fibrillation (AF), which may be independently associated with recurrence of AF after ablation. By conducting CMR, clinical, electrophysiology and biomarker assessment we planned to investigate LV myocardial fibrosis in patients undergoing AF ablation. METHODS: LV fibrosis was assessed by T1 mapping in 31 patients undergoing percutaneous ablation for AF. Galectin-3, coronary sinus type I collagen C terminal telopeptide (ICTP), and type III procollagen N terminal peptide were measured with ELISA. Comparison was made between groups above and below the median for LV extracellular volume fraction (ECV), followed by regression analysis. RESULTS: On linear regression analysis LV ECV had significant associations with invasive left atrial pressure (Beta 0.49, P = 0.008) and coronary sinus ICTP (Beta 0.75, P < 0.001), which remained significant on multivariable regression. CONCLUSION: LV fibrosis in patients with AF is associated with left atrial pressure and invasively measured levels of ICTP turnover biomarker. |
format | Online Article Text |
id | pubmed-7008543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70085432020-02-13 Imaging, biomarker and invasive assessment of diffuse left ventricular myocardial fibrosis in atrial fibrillation Begg, Gordon A. Swoboda, Peter P. Karim, Rashed Oesterlein, Tobias Rhode, Kawal Holden, Arun V. Greenwood, John P. Shantsila, Eduard Lip, Gregory Y. H. Plein, Sven Tayebjee, Muzahir H. J Cardiovasc Magn Reson Research BACKGROUND: Using cardiovascular magnetic resonance imaging (CMR), it is possible to detect diffuse fibrosis of the left ventricle (LV) in patients with atrial fibrillation (AF), which may be independently associated with recurrence of AF after ablation. By conducting CMR, clinical, electrophysiology and biomarker assessment we planned to investigate LV myocardial fibrosis in patients undergoing AF ablation. METHODS: LV fibrosis was assessed by T1 mapping in 31 patients undergoing percutaneous ablation for AF. Galectin-3, coronary sinus type I collagen C terminal telopeptide (ICTP), and type III procollagen N terminal peptide were measured with ELISA. Comparison was made between groups above and below the median for LV extracellular volume fraction (ECV), followed by regression analysis. RESULTS: On linear regression analysis LV ECV had significant associations with invasive left atrial pressure (Beta 0.49, P = 0.008) and coronary sinus ICTP (Beta 0.75, P < 0.001), which remained significant on multivariable regression. CONCLUSION: LV fibrosis in patients with AF is associated with left atrial pressure and invasively measured levels of ICTP turnover biomarker. BioMed Central 2020-02-10 /pmc/articles/PMC7008543/ /pubmed/32036784 http://dx.doi.org/10.1186/s12968-020-0603-y Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Begg, Gordon A. Swoboda, Peter P. Karim, Rashed Oesterlein, Tobias Rhode, Kawal Holden, Arun V. Greenwood, John P. Shantsila, Eduard Lip, Gregory Y. H. Plein, Sven Tayebjee, Muzahir H. Imaging, biomarker and invasive assessment of diffuse left ventricular myocardial fibrosis in atrial fibrillation |
title | Imaging, biomarker and invasive assessment of diffuse left ventricular myocardial fibrosis in atrial fibrillation |
title_full | Imaging, biomarker and invasive assessment of diffuse left ventricular myocardial fibrosis in atrial fibrillation |
title_fullStr | Imaging, biomarker and invasive assessment of diffuse left ventricular myocardial fibrosis in atrial fibrillation |
title_full_unstemmed | Imaging, biomarker and invasive assessment of diffuse left ventricular myocardial fibrosis in atrial fibrillation |
title_short | Imaging, biomarker and invasive assessment of diffuse left ventricular myocardial fibrosis in atrial fibrillation |
title_sort | imaging, biomarker and invasive assessment of diffuse left ventricular myocardial fibrosis in atrial fibrillation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008543/ https://www.ncbi.nlm.nih.gov/pubmed/32036784 http://dx.doi.org/10.1186/s12968-020-0603-y |
work_keys_str_mv | AT begggordona imagingbiomarkerandinvasiveassessmentofdiffuseleftventricularmyocardialfibrosisinatrialfibrillation AT swobodapeterp imagingbiomarkerandinvasiveassessmentofdiffuseleftventricularmyocardialfibrosisinatrialfibrillation AT karimrashed imagingbiomarkerandinvasiveassessmentofdiffuseleftventricularmyocardialfibrosisinatrialfibrillation AT oesterleintobias imagingbiomarkerandinvasiveassessmentofdiffuseleftventricularmyocardialfibrosisinatrialfibrillation AT rhodekawal imagingbiomarkerandinvasiveassessmentofdiffuseleftventricularmyocardialfibrosisinatrialfibrillation AT holdenarunv imagingbiomarkerandinvasiveassessmentofdiffuseleftventricularmyocardialfibrosisinatrialfibrillation AT greenwoodjohnp imagingbiomarkerandinvasiveassessmentofdiffuseleftventricularmyocardialfibrosisinatrialfibrillation AT shantsilaeduard imagingbiomarkerandinvasiveassessmentofdiffuseleftventricularmyocardialfibrosisinatrialfibrillation AT lipgregoryyh imagingbiomarkerandinvasiveassessmentofdiffuseleftventricularmyocardialfibrosisinatrialfibrillation AT pleinsven imagingbiomarkerandinvasiveassessmentofdiffuseleftventricularmyocardialfibrosisinatrialfibrillation AT tayebjeemuzahirh imagingbiomarkerandinvasiveassessmentofdiffuseleftventricularmyocardialfibrosisinatrialfibrillation |